Related Experiment Video
Updated: May 22, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Unlocking the Potential of MicroRNA Expression: Biomarkers for Platelet Reactivity and Coronary Artery Disease
Peter H Nissen1,2, Oliver Buchhave Pedersen3
1Department of Clinical Biochemistry, Thrombosis and Haemostasis Research Group, Aarhus University Hospital, Aarhus, Denmark.
Insights
MicroRNAs (miRNAs) show promise as biomarkers for coronary artery disease (CAD) by regulating platelet function. Standardization is crucial for their reliable use in personalized CAD medicine.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Coronary artery disease (CAD) is a major global health concern, with platelet reactivity central to its development.
- MicroRNAs (miRNAs) are emerging as key regulators of platelet function and potential biomarkers for CAD.
- Specific miRNAs, including miR-223, miR-126, miR-21, and miR-150, influence platelet reactivity and cardiovascular outcomes.
Purpose of the Study:
- To review the role of four key miRNAs (miR-223, miR-126, miR-21, miR-150) in platelet reactivity and their implications for coronary artery disease (CAD).
- To discuss the challenges and inconsistencies in current miRNA research for CAD biomarker development.
- To emphasize the need for standardization in miRNA research methodologies for clinical application.
Main Methods:
- Literature review of studies investigating the role of specific miRNAs in platelet function and CAD.
- Analysis of the impact of various miRNAs on platelet reactivity, thrombus formation, and vascular health.
- Examination of challenges in miRNA biomarker validation, including preanalytical variability and therapeutic influences.
Main Results:
- miR-223 is highly expressed in platelets and associated with CAD and myocardial infarction.
- miR-126 is linked to thrombus formation and vascular health.
- miR-21 and miR-150 also play significant roles in platelet reactivity and cardiovascular outcomes.
Conclusions:
- Despite their potential, variability in miRNA research hinders clinical application as biomarkers for CAD.
- Standardization of sample handling, experimental conditions, and data normalization is essential for reliable miRNA findings.
- Addressing methodological challenges will enable miRNAs to advance personalized medicine for CAD patients, improving treatment strategies and outcomes.
Abstract:
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide, with platelet reactivity playing a central role in its pathogenesis. Recent research has identified microRNAs (miRNAs; miRs) as potential biomarkers for CAD, due to their ability to regulate platelet function and reactivity. This review focuses on four key miRNAs-miR-223, miR-126, miR-21, and miR-150-known to influence platelet reactivity and their implications in CAD. miR-223, which is highly expressed in platelets, has shown associations with CAD and myocardial infarction, while miR-126 has been linked to thrombus formation and vascular health. Additionally, miR-21 and miR-150 have also emerged as important players, with roles in platelet reactivity and cardiovascular outcomes. However, despite their potential, the use of miRNAs as clinical biomarkers faces several challenges, including variability in reported results across studies. These inconsistencies often arise from differences in sample material, preanalytical conditions, and normalization strategies. Furthermore, the influence of antiplatelet therapy on miRNA expression adds another layer of complexity, making it difficult to determine whether observed changes in miRNA levels are due to disease states or therapeutic interventions. This review therefore highlights the need for standardization in miRNA research to enhance the reliability of findings. By addressing these methodological challenges, miRNAs could become powerful tools in personalized medicine, aiding in the development of tailored therapeutic strategies for CAD patients and ultimately improving clinical outcomes.
